The Global Burden of Infectious Respiratory Diseases in Adults: Interview with Three Key Opinion Leaders DOI Creative Commons

Brigitte Scott

EMJ Microbiology & Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 2 - 11

Published: Dec. 24, 2024

According to the WHO, proportion of world’s population aged over 60 years will almost double, from 12% 22%, between 2015–2050. This statistic underscores need focus clinical attention on older adults and risk healthy ageing infectious viral respiratory diseases, including COVID-19, syncytial virus (RSV), influenza, as well other such pertussis, herpes zoster, pneumococcal infections. For this article, EMJ conducted an interview in November 2024 with three key opinion leaders, Archana Chatterjee Chicago Medical School Rosalind Franklin University Medicine Science, North Chicago, Illinois, USA; Stefan Gravenstein Warren Alpert Brown University, Providence, Rhode Island, Tino Schwarz Institute Laboratory Vaccination Centre, Klinikum Würzburg Mitte, Standort Juliusspital, Germany, review global burden diseases adults, explore strategies address burden. The experts provided valuable insights into topics current landscape how it is evolving, lifestyle factors for importance surveillance. Also discussed were challenges associated diagnosis treatment options patients these diseases. Further covered included non-vaccine preventive measures, adult vaccination strategies, barriers implementation adults. explored improve education communication about educating healthcare teams, keeping informed educated topic. Finally, outlined changes they would like see future

Language: Английский

Pertussis Vaccination for Adults: An Updated Guide for Clinicians DOI Creative Commons
Kay Choong See

Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 60 - 60

Published: Jan. 11, 2025

Pertussis, or whooping cough, is a highly contagious respiratory infection caused by the Gram-negative bacterium Bordetella pertussis. Although traditionally associated with children, pertussis increasingly prevalent among adults, particularly those comorbidities weakened immune systems, where it can lead to severe complications. Diagnosing in adults be challenging due its nonspecific symptoms, underreporting, and limited sensitivity of available diagnostic tests. While treatment macrolides generally effective, may not significantly alter clinical course disease, growing concerns about macrolide resistance are emerging. Vaccination remains cornerstone prevention, offering proven immunogenicity, efficacy, safety. However, vaccination uptake low, partly patient awareness insufficient prioritization healthcare professionals. This review aims provide clinicians critical insights into epidemiology, strategies, latest guideline recommendations, empowering them engage meaningful discussions adult patients advocate for increased combat this often-overlooked infection.

Language: Английский

Citations

0
Immunogenicity of GamLPV, an intranasal live vaccine for pertussis prevention, in adult volunteers: a blind, randomised, placebo-controlled trial to optimise the method and schedule of administration DOI Creative Commons
А. А. Лиджиева, A. Yu. Medkovа, S. V. Kulikov

et al.

Biological Products Prevention Diagnosis Treatment, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

INTRODUCTION. Currently used inactivated vaccines with acellular/whole-cell pertussis components do not provide sterilising or sufficiently long-lasting immunity, nor these prevent the spread of pathogen infection. A live vaccine for intranasal administration, GamLPV, has passed necessary preclinical studies and a clinical trial that established optimal dose single-dose vaccination. AIM. This study aimed to optimise method schedule administration GamLPV prevention on basis immunogenicity results obtained in involving healthy volunteers aged 18 40 years. MATERIALS AND METHODS. blind, randomised, placebo-controlled enrolled 50 adults, who were then randomised into two groups according (drops spray). The evaluated efficacy schedules, including vaccination double-dose an interval 60 days. analysed nasopharyngeal oropharyngeal aspirates, serum samples, peripheral blood mononuclear cells from volunteers. levels IgM, IgA, IgG antibodies specific Bordetella secretory IgA measured samples nasal respectively, by enzyme-linked immunosorbent assay. Agglutinating antibody titres determined agglutination tests. quantitative determination B. DNA aspirates real-time polymerase chain reaction. Cell-mediated immune responses assessed production IFN-γ IL-17 cytokines cells. RESULTS. induced -specific observed identified increased total tests, regardless administration. Repeated had pronounced booster effect, as evidenced elevated all classes day 14. Moreover, repeated reduced time clearance bacteria compared after first (from 28 14 days). There no significant differences courses values parameters delivery spray drops. CONCLUSIONS. Intranasal induces humoral cellular mucosal immunity against infection adults. recommended is accelerated second indicative provided vaccination, which can ultimately reduce transmission population.

Language: Английский

Citations

0
Antibody signatures elicited by potent and subpotent whole-cell pertussis vaccines in mice DOI Creative Commons
Yetunde Adewunmi, Jennifer Doering, Prashant Kumar

et al.

Microbiology Spectrum, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

ABSTRACT Inactivated, whole-cell pertussis (wP) vaccines remain at the frontline in global fight against resurgence of whooping cough, especially low- and middle-income countries. However, reliance on intracerebral mouse potency test (ic-MPT or Kendrick assay) as standard batch release assay is extremely burdensome for commercial wP vaccine production. The ic-MPT technically challenging, labor intensive, incongruous with modern animal welfare guidelines. Replacing a Bordetella enzyme-linked immunosorbent assay, so-called serology test, has shown promise but been difficult to implement practice. In this report, we tested hypothesis that potent subpotent have distinct serological profiles mice could be developed substitute ic-MPT. We established an accelerated decay (thermal stress) protocol which wP, context diphtheria-tetanus-whole-cell pertussis, was rendered >10-fold less effective than unstressed when evaluated model B. lung clearance following intranasal challenge. then screened immune sera limited Tahoma I proteome array identified >30 antigens whose antibody reactivity either increased, decreased, were unchanged function potency. Moreover, virtually all “indicator” are known virulence factors reactive human convalescent sera, thereby establishing potential link between infection immunity. These results support development antigen stability-indicating surrogate IMPORTANCE Whooping cough (pertussis) highly contagious respiratory disease caused by Gram-negative bacterium, . Globally, tens millions administered annually. Whole-cell logistically complex manufacture get market because need each laborious challenging involves challenges pertussis. describe efforts develop serology-based relies profiling responses vaccines.

Language: Английский

Citations

0
경북 OO시 일개 정신요양기관에서 발생한 백일해 집단 발생 및 대응 DOI

민제 이,

Chungmin Park, Myung-Jae Hwang

et al.

Public Health Weekly Report, Journal Year: 2025, Volume and Issue: 18(13), P. 525 - 544

Published: Feb. 24, 2025

Citations

0
Pertussis Hospitalizations in France (2008–2020): A Real-World Retrospective Analysis of Incidence and Costs Based on the French National Health Data System DOI Creative Commons
Juan C. Vargas-Zambrano,

Mickael Arnaud,

Ana Antunes

et al.

Journal of Infection and Public Health, Journal Year: 2025, Volume and Issue: unknown, P. 102801 - 102801

Published: May 1, 2025

Language: Английский

Citations

0
pertussis paradox: why are cases increasing despite vaccination efforts? DOI Creative Commons

Katarzyna Błaszczyszyn,

Monika Bolek, Katarzyna Muc

et al.

Quality in Sport, Journal Year: 2024, Volume and Issue: 16, P. 52583 - 52583

Published: July 11, 2024

Introduction Pertussis, a highly transmissible respiratory infection mainly caused by Bordetella pertussis, remains one of the most widespread public health concerns despite establishment global vaccination initiatives. The disease manifests as paroxysmal coughing followed characteristic high-pitched “whooping” sound, and post-tussive vomiting. Severe complications can include pneumonia, encephalopathy, even mortality, particularly in infants. Aim study This aims to provide comprehensive analysis encompassing its clinical presentation, complications, diagnostic methods, epidemiological aspects, strategies, with special focus on development potential impact novel nasal pertussis vaccine. Brief description state knowledge Diagnosis often relies recognizing typical symptoms supported laboratory confirmation through culture polymerase chain reaction testing, or enzyme–linked immunosorbent assays. leads considerable morbidity mortality worldwide, accompanied profound medical, social economic challenges. Summary To address limitations existing vaccines, vaccine has been proposed. elicit robust mucosal immune responses, thereby providing enhanced protection against preventing asymptomatic transmission pertussis. offers detailed examination statistics support analysis, valuable insights into epidemiology, highlighting need for improved strategies mitigate disease's impact.

Language: Английский

Citations

0
Prevalence and clinical relevance of comorbid pertussis infection in adult patients with asthma: A prospective, cross-sectional study DOI

Hirono Nishiyama,

Tomoko Tajiri, Ryo Kurokawa

et al.

Respiratory Investigation, Journal Year: 2024, Volume and Issue: 62(5), P. 811 - 816

Published: July 16, 2024

Language: Английский

Citations

0
Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions DOI Creative Commons
A-Reum Kim, Alessandro Sette, Ricardo da Silva Antunes

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 705 - 714

Published: July 22, 2024

Whooping cough, also known as pertussis, remains a significant challenge vaccine-preventable disease worldwide. Since the switch from whole-cell Pertussis (wP) vaccine to acellular (aP), cases of whooping cough have increased in countries using aP vaccine. Understanding immune system's response pertussis vaccines and infection is crucial for improving current efficacy.

Language: Английский

Citations

0
Javaslatok és megfontolások a magyarországi pertussisesetszám-növekedéssel összefüggésben DOI Creative Commons

Diána Tróbert-Sipos,

Tamás Pék,

Andrea Kulcsár

et al.

Orvosi Hetilap, Journal Year: 2024, Volume and Issue: 165(34), P. 1307 - 1318

Published: Aug. 25, 2024

Európa-szerte a szamárköhögés robbanásszerű emelkedését figyelhetjük meg. Az idei év első 3 hónapjában már több igazolt esetet regisztráltak, mint tavalyi évben összesen. Magyarországon pertussis epidemiológiai helyzete közelmúltban igen kedvezően alakult, 2019 és 2023 között bejelentett esetszámok mediánja 2 fő volt. A növekvő incidenciát azonban hazánkban is észleljük: 2024. július 14-ig 153 jelentett pertussismegbetegedésről számolhatunk be. fenyegető közösségi terjedés megfékezése megváltozott prevenciós hozzáállást fokozott diagnosztikus aktivitást kíván. kontaktszemélyek mihamarabbi azonosítása ellátása alapvető fontosságú. betegség az oltatlan, illetve nem teljeskörűen oltott újszülöttekre csecsemőkre legveszélyesebb. Esetükben köhögési rohamok kapcsán jelentkező apnoés epizódok keringés- légzésleálláshoz vezethetnek. elsődleges cél ennek populációnak védelme, melynek leghatásosabb módja életkor szerinti kötelező immunizáció késedelem nélküli elvégzése, fészekimmunitás biztosítása várandós nők aktív immunizálása. várandósok pertussisoltását évtizedek óta biztonsággal nagy hatékonysággal végzik világszerte. 16–36. gestatiós hét bármikor alkalmazható, de 27–31. legoptimálisabb. Közleményünkben korszerű nemzetközi irányelvek alapján javaslatokat teszünk diagnosztikájára, kezelésére, posztexpozíciós kemoprofilaxisra, valamint immunizációra. klinikai gyakorlathoz adott javaslataink kizárólag jelenlegi hazai járványügyi helyzetben érvényesek, aktuális hatósági ajánlás megjelenéséig. Orv Hetil. 2024; 165(34): 1307–1318.

Citations

0
The Global Burden of Infectious Respiratory Diseases in Adults: Interview with Three Key Opinion Leaders DOI Creative Commons

Brigitte Scott

EMJ Microbiology & Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 2 - 11

Published: Dec. 24, 2024

According to the WHO, proportion of world’s population aged over 60 years will almost double, from 12% 22%, between 2015–2050. This statistic underscores need focus clinical attention on older adults and risk healthy ageing infectious viral respiratory diseases, including COVID-19, syncytial virus (RSV), influenza, as well other such pertussis, herpes zoster, pneumococcal infections. For this article, EMJ conducted an interview in November 2024 with three key opinion leaders, Archana Chatterjee Chicago Medical School Rosalind Franklin University Medicine Science, North Chicago, Illinois, USA; Stefan Gravenstein Warren Alpert Brown University, Providence, Rhode Island, Tino Schwarz Institute Laboratory Vaccination Centre, Klinikum Würzburg Mitte, Standort Juliusspital, Germany, review global burden diseases adults, explore strategies address burden. The experts provided valuable insights into topics current landscape how it is evolving, lifestyle factors for importance surveillance. Also discussed were challenges associated diagnosis treatment options patients these diseases. Further covered included non-vaccine preventive measures, adult vaccination strategies, barriers implementation adults. explored improve education communication about educating healthcare teams, keeping informed educated topic. Finally, outlined changes they would like see future

Language: Английский

Citations

0